Agreement with Eli Lilly and Company (Tables)

6 Months Ended

Jun. 30, 2019

Agreement with Eli Lilly and Company

Summary of deferred revenue included in the Company’s balance sheets

As of June 30, 2019, deferred revenue included in the Company’s balance sheets comprised the following (in thousands):

	June 30,		December 31,
	2019		2018
		(unaudited)
Deferred revenue, beginning of period	$	26,725	$	—
Up-front payment		—		25,000
Attributed premium on the proceeds from Lilly’s investment in the Company		—		1,725
Research and development support billing		1,000		—
Revenue from research and development arrangement recognized		(2,759)		—
Total deferred revenue, end of period		24,966		26,725
Less: Deferred revenue, current portion		(6,524)		(4,989)
Deferred revenue, non-current portion	$	18,442	$	21,736